Warning: Clinic Releaf® are deliberately charging patients over MSRP for medication through a partner pharmacy, without making other pharmacies available to their patients.
All patients must be offered free choice in pharmacy without influence nor penalty to avoid non-compliant 'prescription direction' breaking GMC and BMA guidelines - risking prescribing clinician's licence to practice.

Sapphire Access Scheme

Sapphire Access Scheme

From Curaleaf/Rokshaw

Sapphire launches the UK’s first Medical Cannabis Registry and offers the first 1,000 patients reduced costs to be involved.

Sapphire Medical Clinics, the first medical cannabis clinic approved to see patients by the Care Quality Commission, has today launched a ground-breaking initiative to rapidly expand the evidence base for medical cannabis. The launch of the Sapphire Access Scheme via the UK Medical Cannabis Registry will collect and analyse clinical information on patients taking medical cannabis treatments.

Sapphire patients will be offered reduced appointment costs in recognition of their contribution to the UK’s Medical Cannabis Registry and Real World Evidence data platform. This benefit is in addition to the reduced cost of telemedicine appointments Sapphire Medical Clinics announced in March. Patients are supported through the full process from eligibility through to appointment and when appropriate prescription, delivered straight to their front door.

Who is Eligible?

Sapphire Medical Clinics provides an expert clinical opinion for any patient who has failed to achieve adequate benefit from first line therapies for any condition where there is clinical evidence for the use of medical cannabis. Those that receive the prescription can join the scheme and contribute to advancing the evidence for medical cannabis.

The UK Medical Cannabis Registry will be free to contribute to for any patient in the UK with a prescription who wants to progress the science of medical cannabis.

Dr Mikael Sodergren, Managing Director and Academic Lead at Sapphire Clinics, said ‘We are very proud to launch the Sapphire Access Scheme which ultimately aims to provide the Real-World Evidence to allow patients to access cannabis-based medicines on the NHS for all the conditions in which there is proven clinical benefit.’

Patients on the Sapphire Access scheme will also receive greater insight into how their treatment is affecting them via the Real World Evidence Platform. A Sapphire patient, Laura Drummond, 40 years old from Hampshire, Fibromyalgia ‘I love the idea of contributing to the growing evidence which no doubt will help many others in the future. The reduced appointment costs via the Sapphire Access Scheme means that money is less of a concern when addressing my healthcare needs.’

Dr Michael Platt, Medical Director of Sapphire Clinics, added: ‘There are an estimated 1.4 million medical cannabis patients in the UK and with this initiative we hope to make it more affordable for them to access medication through a recognised clinic where we can carefully monitor their treatment.’

Centre for Medicinal Cannabis (CMC) welcomed this announcement. Dr Andy Yates, Pharmacy Lead at CMC commented ‘We are delighted to see initiatives such as this from the Sapphire Clinics be rolled out. The message from the UK and around the world is the same; HCPs, regulators, and patients want access to robust data on the use of cannabis medicines to provide the evidence to confidently use these medicines appropriately and safely. We encourage all patients and HCPs to contribute to this important database’.

Further details can be found here.

Participating Clinics

Sapphire Curaleaf® Clinic
Sapphire Medical Clinics Ltd
England London, England
020 7459 4075
£210.00 Sign-Up
(Switch for £0)
£125.00 Consults Free Repeats

This page was last updated: . Please email MedBud with any required updates or corrections.

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)